Skip to main content
SpringerLink
Log in

Invasive Oesophageal Candidiasis

Current and Developing Treatment Options

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10% of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addition, unless the underlying immunodeficiency is corrected, approximately 60% of patients will experience a relapse within 6 months of the initial infection. The systemic azoles have gradually replaced the use of amphotericin B for oesophageal candidiasis, and are generally safely used and effective agents for this infection. A concern in some of these patients is the appearance of antifungal-refractory oesophageal candidiasis, which frequently leads to a vicious cycle of poor oral intake, weight loss, malnutrition and wasting syndrome, with occasional mortality due to malnutrition. Newer antifungals such as voriconazole and caspofungin, which are more potent in vitro and have a broader spectrum of activity, including activity against fluconazole-resistant Candida species are a welcome addition to the antifungal armamentarium that may be used in the management of refractory mucosal candidiasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

References

  1. Berkhout CM. De Schimmelgeschlachter Monilia, Oidium, Vospora, en Torula [dissertation]. Utrecht: University of Utrecht, 1923

    Google Scholar 

  2. Odds FC, editor. Candida and candidosis. 2nd ed. London: Bailliere Tindall, 1988

    Google Scholar 

  3. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30(4): 662–78

    Article  CAS  Google Scholar 

  4. Vazquez JA, Sobel JD, Peng G, et al. Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Clin Infect Dis 1999; 28(5): 1025–31

    Article  PubMed  CAS  Google Scholar 

  5. Sobel JD, Ohmit SE, Schuman P, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001; 183(2): 286–93

    Article  PubMed  CAS  Google Scholar 

  6. Kwon-Chung KJ, Bennett JE, editors. Medical mycology. Philadelphia (PA): Lea & Febiger, 1992

    Google Scholar 

  7. Rippon JW, editor. The pathogenic fungi and pathogenic actino-mycetes. 3rd ed. Philadelphia (PA): WB Saunders, 1988

    Google Scholar 

  8. Pfaller MA, Houston A, Coffmann S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (torulopsis) glabrata. J Clin Microbiol 1996; 34(1): 58–61

    PubMed  CAS  Google Scholar 

  9. Do-Carmo-Sousa L. Distribution of yeasts in nature. In: Rose AH, Harrison JS, editors. The yeasts. London: Academic Press, 1969: 79–105

    Google Scholar 

  10. Vazquez JA, Sanchez V, Dmuchowski C, et al. Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis 1993; 168(1): 195–201

    Article  PubMed  CAS  Google Scholar 

  11. Wade JC, Schimpff SC. Epidemiology and prevention of Candida infections. In: Bodey GP, Fainstain V, editors. Candidiasis. New York: Raven Press, 1985: 111–33

    Google Scholar 

  12. Marples MJ. Microbiological studies in Western Samoa: II. The isolation of yeast-like organisms from the mouth. Trans R Soc Trop Med Hyg 1960; 54: 166–70

    CAS  Google Scholar 

  13. Smith BJ, Pman AP, Arblasto PG. Incidence of Candida in hospital in-patients and the effects of antibiotic therapy. BMJ 1966; 1: 208–10

    Article  Google Scholar 

  14. Kennedy MJ. Regulation of Candida albicans populations in the gastrointestinal tract. In: McGinnis MR, editor. Current topics in medical mycology. New York: Springer-Verlag, 1989: 315–402

    Chapter  Google Scholar 

  15. Cohen R, Roth FJ, Delgado F, et al. Fungal flora of the normal human small and large intestine. N Engl J Med 1969; 280: 638–41

    Article  PubMed  CAS  Google Scholar 

  16. Sakata H, Fujita K, Yahioka H. The effects of antimicrobial agents on the fecal flora of children. Antimicrob Agents Chemother 1986; 29: 225–9

    Article  PubMed  CAS  Google Scholar 

  17. Mackenzie DWR. Yeast from human sources. Sabouraudia 1962; 1: 8–15

    Article  Google Scholar 

  18. Cambon M, Petavy AF, Guillot J, et al. Etude de la frequence des protozoaires et des levuires isoles du parodonte chez 509 sujets. Pathol Biol (Paris) 1979; 27: 603–6

    CAS  Google Scholar 

  19. Fidel Jr PL, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80–96

    Google Scholar 

  20. Gumbo T, Isada CM, Hall G, et al. Candida glabrata fungemia: clinical features of 139 patients. Medicine 1999; 78: 220–7

    Article  PubMed  CAS  Google Scholar 

  21. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39(9): 3254–9

    Article  PubMed  CAS  Google Scholar 

  22. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 2000; 1(1): 47–59

    Article  PubMed  CAS  Google Scholar 

  23. Stenderup A, Schonheyder H. Mycoses complicating AIDS. Microbiol Sci 1984; 1: 219–23

    PubMed  CAS  Google Scholar 

  24. Girmenia C, Martino P, De Bernardis F, et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23(3): 506–14

    Article  PubMed  CAS  Google Scholar 

  25. Levy I, Rubin LG, Vasishtha S, et al. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1998; 26(5): 1086–8

    Article  PubMed  CAS  Google Scholar 

  26. Sanchez V, Vazquez JA, Barth-Jones D, et al. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 1993; 94(6): 577–82

    Article  PubMed  CAS  Google Scholar 

  27. Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungemia: an escalating serious infection in immunocompromised patients. Arch Intern Med 2000; 160(17): 2659–64

    Article  PubMed  CAS  Google Scholar 

  28. Merz WG, Karp JE, Schron D, et al. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986; 24: 581–4

    PubMed  CAS  Google Scholar 

  29. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. Antimicrob Agents Chemother 1991; 37: 1847–9

    Article  Google Scholar 

  30. Sullivan D, Coleman D. Candida dubliniensis: characteristics and identification. J Clin Microbiol 1998; 36: 329–34

    PubMed  CAS  Google Scholar 

  31. Sullivan DJ, Westerneng TJ, Haynes KA, et al. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995; 141(7): 1507–21

    CAS  Google Scholar 

  32. Hidalgo JA, Brown W, Vazquez JA. Invasive C. dubliniensis in an HIV-negative patient: a new opportunistic fungal pathogen. Infect Dis Clin Pract 2000; 9: 176–9

    Google Scholar 

  33. Sebti A, Kiehn TE, Perlin D, et al. Candida dubliniensis at a cancer center. Clin Infect Dis 2001; 32(7): 1034–8

    Article  PubMed  CAS  Google Scholar 

  34. Jabra-Rizk MA, Baqui AA, Kelley JI, et al. Identification of Candida dubliniensis in a prospective study of patients in the United States. J Clin Microbiol 1999; 37(2): 321–6

    PubMed  CAS  Google Scholar 

  35. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8(4): 462–78

    PubMed  CAS  Google Scholar 

  36. Vazquez JA, Lundstrom T, Dembry L, et al. Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis. Bone Marrow Transplant 1995; 16(6): 849–53

    PubMed  CAS  Google Scholar 

  37. Sanchez V, Vazquez JA, Barth-Jones D, et al. Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol 1992; 30(11): 3005–8

    PubMed  CAS  Google Scholar 

  38. Yoon SA, Vazquez JA, Steffan PE, et al. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother 1999; 43(4): 836–45

    PubMed  CAS  Google Scholar 

  39. Bodey GP, Anaissie EJ, Edwards JE. Definitions of Candida infections. In: Bodey GP, editor. Candidiasis: pathogenesis, diagnosis, and treatment. New York: Raven Press Ltd, 1993: 407–8

    Google Scholar 

  40. Kwon-Chung KJ, Riggsby WS, Uphoff RA, et al. Genetic differences between type I and type II Candida stellatoidea. Infect Immun 1989; 57(2): 527–32

    PubMed  CAS  Google Scholar 

  41. Rikkerink EH, Magee BB, Magee PT. Genomic structure of Candida stellatoidea: extra chromosomes and gene duplication. Infect Immun 1990; 58(4): 949–4

    PubMed  CAS  Google Scholar 

  42. Soll DR. The ins and outs of DNA fingerprinting the infectious fungi. Clin Microbiol Rev 2000; 13(2): 332–70

    Article  PubMed  CAS  Google Scholar 

  43. Odds FC. Candida albicans, the life and times of a pathogenic yeast. J Med Vet Mycol 1994; 32 Suppl. 1: 1–8

    Article  PubMed  Google Scholar 

  44. Pfaller MA, Cabezudo I, Hollis R, et al. The use of biotyping and DNA fingerprinting in typing Candida albicans from hospitalized patients. Diagn Microbiol Infect Dis 1990; 13(6): 481–9

    Article  PubMed  CAS  Google Scholar 

  45. Berger C, Frei R, Gratwohl A, et al. Bottled lemon juice: a cryptic source of invasive Candida infections in the immunocompromised host. J Infect Dis 1988; 158(3): 654–5

    Article  PubMed  CAS  Google Scholar 

  46. Galen 130-ca. 200. Des remedius parabilibus I-III. In: Kuhn CG. Opera Omnia. Hildersheim: George Olms, 1965

    Google Scholar 

  47. Taschdjian CL, Kozinn PJ. Laboratory and clinical studies on candidiasis in the newborn infant. J Pediatrics 1957; 50: 426–33

    Article  CAS  Google Scholar 

  48. Kozinn PJ, Taschdjian CL, Dragutsky D. Therapy of oral thrush; a comparative evaluation of gentian violet, mycostatin, and amphotericin B. Monogr Ther 1957; 2: 16–24

    Google Scholar 

  49. Rothschild H, Wilson M, Lopez M, et al. An immunological investigation of a family with chronic mucocutaneous candidiasis. Int Arch Allergy Appl Immunol 1976; 52: 291–6

    Article  PubMed  CAS  Google Scholar 

  50. Sams Jr WM, Tomzzo JL, Snyderman R, et al. Chronic mucocutaneous candidiasis. Am J Med 1979; 67: 948–59

    Article  PubMed  Google Scholar 

  51. Beta PG. Pathology of some of the opportunistic infections in acquired immune deficiency syndrome (AIDS). Pathologica 1985; 77: 67–75

    Google Scholar 

  52. Chandler FW. Pathology of the mycoses in patients with the acquired immune deficiency syndrome (AIDS). Curr Top Med Mycol 1986; 1: 1–23

    Article  Google Scholar 

  53. Jaffe HW, Bergman DJ, Selik RM. Acquired immune deficiency syndrome in the United States, the first 1000 cases. J Infect Dis 1983; 148: 339–45

    Article  PubMed  CAS  Google Scholar 

  54. Melbye M, Schonheyder H, Kesters L, et al. Carriage of oral C. albicans associated with a high number of circulating suppressor T Lymphocytes. J Infect Dis 1985; 152: 1356–7

    CAS  Google Scholar 

  55. Schnheyder H, Melbye M, Biggar RJ, et al. Oral yeast flora and antibodies to Candida albicans in homosexual men. Mykosen 1984; 27: 539–44

    Article  Google Scholar 

  56. Kalo-Klein A, Witkin SS. Prostaglandin E2 enhances and gamma interferon inhibits germ tube formation in Candida albicans. Infect Immun 1990; 58: 260–2

    PubMed  CAS  Google Scholar 

  57. Sobel JD, Vazquez JA. Fungal infections of the gastrointestinal tract. In: Surawicz C, Owen T, editors. Gastrointestinal and hepatic infections. Philadelphia (PA): WB Saunders, 1995: 219–45

    Google Scholar 

  58. Topper-James L, Aldred MJ, Walker DM. Candidal infections and populations of Candida albicans in mouths of diabetics. J Clin Pathol 1981; 4: 706–11

    Article  Google Scholar 

  59. Segal E, Sotoka A, Schechter A. Correlative relationship between adherence of Candida albicans to human vaginal epithelial cells in vitro and candidal vaginitis. J Med Vet Mycol 1984; 22: 191–200

    Article  CAS  Google Scholar 

  60. Wilson RM, Reeves WG. Neutrophil phagocytosis and killing in insulin-dependent diabetes. Clin Exp Immunol 1986; 63: 478–84

    PubMed  CAS  Google Scholar 

  61. Sutptin A, Albright F, McCure DJ. Five cases of idiopathic hypoparathyroidism associated with moniliasis. J Clin Endocrinol 1943; 3: 625–30

    Article  Google Scholar 

  62. Spinner MW, Blizzard RM, Childs B. Clinical and genetic heterogeneity in idiopathic Addison's disease and hypoparathyroidism. J Clin Endocrinol 1968; 28: 795–804

    Article  CAS  Google Scholar 

  63. Podolsky S, Ferguson BD. Fatal systemic candidiasis following treatment of Addisonian crisis in a juvenile diabetic. Diabetes 1970; 19: 438–44

    PubMed  CAS  Google Scholar 

  64. Giombetti R, Hagstrom JWC, Landey S, et al. Cushing's syndrome in infancy: a case complicated by monilial endocarditis. Am J Dis Child 1971; 122: 264–6

    PubMed  CAS  Google Scholar 

  65. Cormane RH, Goolings WRO. Factors influencing the growth of Candida albicans. Sabouraudia 1963; 3: 52–63

    Article  PubMed  CAS  Google Scholar 

  66. Samaranayake LP. Nutritional factors and oral candidosis. J Oral Pathol 1986; 15: 61–5

    Article  PubMed  CAS  Google Scholar 

  67. Seelig MS. The role of antibiotics in the pathogenesis of Candida infections. Am J Med 1966; 40: 887–917

    Article  PubMed  CAS  Google Scholar 

  68. Fitzpatrick JJ, Topley HE. Ampicillin therapy and Candida overgrowth. Am J Med Sci 1966; 252: 310–3

    Article  PubMed  CAS  Google Scholar 

  69. Caldwell JR, Cluff LE. Adverse reactions to antimicrobial agents. JAMA 1974; 230: 77–80

    Article  PubMed  CAS  Google Scholar 

  70. Winner HI, Hurley R. Candida albicans. London: Churchill, 1964

    Google Scholar 

  71. Johnston RD, Chick EW, Johnston NS. Asymptomatic quantitative increase of Candida albicans in the oral cavity: predisposing factors. South Med J 1967; 60: 1244–7

    Article  PubMed  CAS  Google Scholar 

  72. Loose DS, Feldman D. Characterization of a unique corticoste-rone-binding protein in Candida albicans. J Biol Chem 1982; 257: 4925–30

    PubMed  CAS  Google Scholar 

  73. Sanford GR, Metz WG, Wingard JR, et al. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980; 142: 503–9

    Article  Google Scholar 

  74. Kleinegger CL, Lockhart SR, Vargas K, et al. Frequency, intensity, species and strains of oral Candida vary as a function of host age. J Clin Microbiol 1996; 34: 2246–54

    PubMed  CAS  Google Scholar 

  75. Walsh TJ, Merz WG. Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis. Am J Clin Pathol 1986; 85: 498–502

    PubMed  CAS  Google Scholar 

  76. Bennet JE. Diagnosis and management of candidiasis in the immunosuppressed host. Scand J Infect Dis 1978; 16 Suppl.: 83–6

    Google Scholar 

  77. Mekalanos JJ. Environmental signals controlling expression of virulence determinants in bacteria. J Bacteriol 1992; 174(1): 1–7

    PubMed  CAS  Google Scholar 

  78. De Bernardis F, Muhlschlegel FA, Cassone A, et al. The pH of the host niche controls gene expression in and virulence of Candida albicans. Infect Immun 1998; 66: 3317–25

    PubMed  Google Scholar 

  79. Brown AJ, Gow NA. Regulatory networks controlling Candida albicans morphogenesis. Trends Microbiol 1999; 7(8): 333–8

    Article  PubMed  CAS  Google Scholar 

  80. Sundstrom P. Adhesins in Candida albicans. Curr Opin Microbiol 1999; 2(4): 353–7

    Article  PubMed  CAS  Google Scholar 

  81. Staab JF, Bradway SD, Fidel PL, et al. Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp 1. Science 1999; 283(5407): 1535–8

    Article  PubMed  CAS  Google Scholar 

  82. Leidich SD, Ibrahim AS, Fu Y, et al. Cloning and disruption of caPLB1, a phospholipase B gene involvedinthe pathogenicity of Candida albicans. J Biol Chem 1998; 273(40): 2678–86

    Article  Google Scholar 

  83. Monod M, Togni G, Hube B, et al. Multiplicity of genes encoding secreted aspartic proteinases in Candida species. Mol Microbiol 1994; 13(2): 357–68

    Article  PubMed  CAS  Google Scholar 

  84. Hipocrates CA, Adams F. Epidemics 460-377 BC, Book 3. Baltimore (MD): Williams and Wilkins, 1939

    Google Scholar 

  85. Trousseau A. Lectures on clinical medicine, delivered on the Hotel-Dieu, Paris, Vol. 2 [Cormack JR, translated from 1865 edition]. London: New Sydenham Society, 1869

    Google Scholar 

  86. Parrot J. Cliniques des Noruvea-n s L'athrepsie., Lecons Recuellies par Dr. Paris: Troisier G. Masson, 1877

    Google Scholar 

  87. Langenbeck B. Auffingung von pilzer aus der Schleimhaut der Speiseröhre einer typhus-leiche: neue not geb. Natur-u-Heilk 1939; 12: 145–7

    Google Scholar 

  88. Berg FT. GM Torsk hos Barn. Stockholm: LJ Hjerta, 1846

    Google Scholar 

  89. Haussmann D. Parasites de organes sexuals femeil-les de l'homme et de quelques animaux avec une notice sur development de l'Oidium albicans Robin. Paris: JB Bailliere, 1875

    Google Scholar 

  90. Eras P, Goldstein MJ, Sherlock P. Candida infection of the gastrointestinal tract. Medicine 1972; 51(5): 367–79

    Article  PubMed  CAS  Google Scholar 

  91. Stevens DA. Fungal infections in AIDS patients. Br J Clin Pract Suppl 1990; 71(44): 11–22

    PubMed  CAS  Google Scholar 

  92. Coleman DC, Bennett DE, Sullivan DJ, et al. Oral Candida in HIV infection and AIDS: new perspectives/new approaches. Critical Rev Microbiol 1993; 19(2): 61–82

    Article  CAS  Google Scholar 

  93. Wheeler RR, Peacock Jr JE, Cruz JM, et al. Esophagitis in the immunocompromised host: role of esophagoscopy in diagnosis. Rev Infect Dis 1987; 9(1): 88–96

    Article  PubMed  CAS  Google Scholar 

  94. Jensen KB, Stenderup A, Thomsen JB. Esophageal moniliasis in malignant neoplastic disease. Acta Med Scand 1964; 175: 455–9

    Article  PubMed  CAS  Google Scholar 

  95. Minoli G, Terrazzi V, Rossini A. Gastroduodenal candidiasis occurring without underlying disease: report on 2 cases. Endoscopy 1979; 11: 18–22

    Article  PubMed  CAS  Google Scholar 

  96. Clotet B, Grifol M, Parra O, et al. Asymptomatic esophageal candidiasis in the acquired-immunodeficiency-syndrome-related complex [letter]. Ann Intern Med 1986; 105(1): 145

    PubMed  CAS  Google Scholar 

  97. Kodsi BE, Wickremesinghe C, Kozinn PJ, et al. Candida esophagitis: a prospective study of 27 cases. Gastroenterology 1976; 1(5): 715–9

    Google Scholar 

  98. Lefkowitz M, Elsas LJ, Levine RJ. Candida infection complicating peptic esophageal ulcer: infection in an aortic-esophageal fistula. Arch Intern Med 1964; 113: 672–5

    Article  PubMed  CAS  Google Scholar 

  99. Sehhat S, Hazeghi K, Bajoghli M, et al. Oesophageal moniliasis causing fistula formation and lung abscess. Thorax 1976; 1(3): 361–4

    Article  Google Scholar 

  100. Athey PA, Goldstein HM, Dodd GD. Radiologic spectrum of opportunistic infections of the upper gastrointestinal tract. Am J Roentgenol 1977; 129(3): 419–24

    CAS  Google Scholar 

  101. Pagani JJ, Libshitz HI. Radiology of Candida infections. In: Bodey GP, Fainstain V, editors. Candidiasis. New York: Raven Press, 1981: 71–84

    Google Scholar 

  102. Pfaller MA, Messer SA, Gee S, et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999; 37(3): 870–2

    PubMed  CAS  Google Scholar 

  103. Vazquez JA, Lynch M, Sobel JD. In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species. Antimicrob Agents Chemother 1995; 39(12): 2689–91

    Article  PubMed  CAS  Google Scholar 

  104. Minari A, Hachem R, Raad I. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin Infect Dis 2001; 32(2): 186–90

    Article  PubMed  CAS  Google Scholar 

  105. Bhargava P, Vazquez JA. Amphotericin B-resistant Candida krusei?. A comparison of standardized testing and time kill studies. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 924

  106. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A. Wayne (PA): National Committee for Clinical Laboratory Standards, 1997

    Google Scholar 

  107. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24(2): 235–47

    CAS  Google Scholar 

  108. Quereda C, Polanco AM, Giner C, et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oro-pharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996; 15(1): 30–7

    Article  PubMed  CAS  Google Scholar 

  109. Stiller RL, Bennett JE, Scholer HJ, et al. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother 1982; 22(3): 482–7

    Article  PubMed  CAS  Google Scholar 

  110. Witt MD, Imhoff T, Li C, et al. Comparison of fluconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-C. albicans strains. Antimicrob Agents Chemother 1993; 37(9): 2030–2

    Article  CAS  Google Scholar 

  111. Law D, Moore CB, Denning DW. Amphotericin B resistance testing of Candida spp.: a comparison of methods. J Antimicrob Chemother 1997; 40(1): 117–9

    Article  Google Scholar 

  112. Karyotakis NC, Anaissie EJ. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob Agents Chemother 1994; 38(11): 2660–2

    Article  PubMed  CAS  Google Scholar 

  113. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155: 1093–8

    Article  PubMed  CAS  Google Scholar 

  114. Anaissie E, Paetznick V, Bodey GP. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading [published erratum appears in Antimicrob Agents Chemother 1992 May; 36 (5): 1170]. Antimicrob Agents Chemother 1991; 35(8): 1641–6

    Article  PubMed  CAS  Google Scholar 

  115. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877–916

    Article  PubMed  CAS  Google Scholar 

  116. Hughes CE, Beggs WH. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother 1987; 19: 171–4

    Article  PubMed  CAS  Google Scholar 

  117. Kurtz MB, Rex JH. Glucan synthase inhibitors as antifungal agents. Adv Protein Chem 2001; 56: 423–75

    Article  PubMed  CAS  Google Scholar 

  118. Ginsburg CH, Braden GL, Tauber AI, et al. Oral clotrimazole in the treatment of esophageal candidiasis. Am J Med Sci 1981; 71(5): 891–5

    Article  CAS  Google Scholar 

  119. Dewit S, Urbain D, Rahir F, et al. Efficacy of oral fluconazole in the treatment of AIDS-associated esophageal candidiasis. Eur J Clin Microbiol Infect Dis 1991; 10: 503–5

    Article  CAS  Google Scholar 

  120. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26(2): 259–72

    Article  PubMed  CAS  Google Scholar 

  121. Horsburgh CR, Kirkpatrick CH. Long term therapy of chronic mucocutaneous candidiasis with ketoconazole; experience with 21 patients. Am J Med 1983; 74 Suppl. 1B: 23–9

    Article  PubMed  Google Scholar 

  122. Hughes WT, Bartley DL, Patterson GG, et al. Ketoconazole and candidiasis: a controlled study. J Infect Dis 1983; 147(6): 1060–3

    Article  PubMed  CAS  Google Scholar 

  123. Fazio RA, Wickremesinghe PC, Arsura EL. Ketoconazole treatment of Candida esophagitis: a prospective study of 12 cases. Am J Gastroenterol 1983; 78(5): 261–4

    PubMed  CAS  Google Scholar 

  124. Wilcox CM, Darouiche RO, Laine L, et al. A randomized, double-blinded comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176: 227–32

    Article  PubMed  CAS  Google Scholar 

  125. Barbara G, Barbarini G, DiLorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis 1995; 27(6): 613–7

    Article  Google Scholar 

  126. Barbara G, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 1996; 111: 1169–77

    Article  Google Scholar 

  127. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20(1): 115–25

    Article  PubMed  CAS  Google Scholar 

  128. Maenza JR, Merz WG, Romagnoli MJ, et al. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24(1): 28–34

    Article  PubMed  CAS  Google Scholar 

  129. MedoffG,Dismukes WE, Meade III RH, et al. A new therapeutic approach to Candida infections, a preliminary report. Arch Intern Med 1972; 130: 241–5

    Article  Google Scholar 

  130. Scott BB, Jenkins D. Gastro-oesophageal candidiasis. Gut 1982; 23: 137–9

    Article  PubMed  CAS  Google Scholar 

  131. Tavitian A, Raufman JP, Rosenthal LE, et al. Ketoconazole resistant Candida esophagitis in patients with acquired immu-nodefieiency syndrome. Gastroenterology 1986; 90: 443–5

    PubMed  CAS  Google Scholar 

  132. Glatt AE, Chirgwin K, Landesman SH. Treatment of infections associated with human immunodeficiency virus. N Engl J Med 1988; 18: 1439–48

    Article  Google Scholar 

  133. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173(1): 219–25

    Article  PubMed  CAS  Google Scholar 

  134. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96(6): 2055–61

    PubMed  CAS  Google Scholar 

  135. Mori T, Matsumura M, Kanamaru Y, et al. Myelofibrosis complicated by infection due to Candida albicans: emergence of resistance to antifungal agents during therapy. Clin Infect Dis 1997; 25: 1470–1

    Article  PubMed  CAS  Google Scholar 

  136. Xu J, Ramos AR, Vilgalys R, et al. Clonal and spontaneous origins of fluconazole resistance in Candida albicans. J Clin Microbiol 2000; 38(3): 1214–20

    PubMed  CAS  Google Scholar 

  137. Polak A. Multicenter study of the standardization of sensitivity testing of fungi to 5-fluorocytosine and amphotericin B. Mykosen 1987; 30(7): 306–8, 311-4

    PubMed  CAS  Google Scholar 

  138. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993; 36(11–12): 421–4

    PubMed  CAS  Google Scholar 

  139. Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother 1995; 39(8): 1779–83

    Article  PubMed  CAS  Google Scholar 

  140. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995; 39(9): 1907–12

    Article  PubMed  CAS  Google Scholar 

  141. Sugar AM, Hitchcock CA, Troke PF, et al. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995; 39(3): 598–601

    Article  PubMed  CAS  Google Scholar 

  142. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000; 30(5): 749–56

    Article  PubMed  CAS  Google Scholar 

  143. Revankar SG, Dib O, Kirkpatrick WR, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in Human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26: 960–3

    Article  PubMed  CAS  Google Scholar 

  144. Martins MD, Rex JH. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann Intern Med 1997; 126(4): 332–3

    PubMed  CAS  Google Scholar 

  145. Parving H. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann Intern Med 1997; 126: 332–3

    Google Scholar 

  146. Vazquez JA, Gupta S, Villanueva A. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis 1998; 17(11): 781–3

    Article  PubMed  CAS  Google Scholar 

  147. Vazquez J, Lamarca A, Schwartz R, et al. Management of fluconazole-refractory oropharyngeal candidiasis using high-dose terbinafine in patients with AIDS. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 1418

  148. Ernst EJ. Investigational antifungal agents. Pharmacotherapy 2001; 21 (8 Pt 2): 165S–74S

    Article  PubMed  CAS  Google Scholar 

  149. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12(1): 40–79

    PubMed  CAS  Google Scholar 

  150. Ghannoum MA, Kuhn DM. Voriconazole-better chances for patients with invasive mycoses. Eur J Med Res 2002; 7: 242–56

    PubMed  CAS  Google Scholar 

  151. Ally R, Schurmann D, Kreisel W, et al. A randomized, doubleblind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33(9): 1447–54

    Article  PubMed  CAS  Google Scholar 

  152. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41(3): 575–7

    PubMed  CAS  Google Scholar 

  153. Hussain MA, Reyes GH, Ghannoum MA. Newer antifungal agents and treatment strategies. Rev Med Microbiol 2001; 12 Suppl. 1: S3–S12

    Google Scholar 

  154. St-Germain G, Dion C, Espinel-Ingroff A, et al. Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV. J Antimicrob Chemother 1995; 36(1): 109–18

    Article  PubMed  CAS  Google Scholar 

  155. Eichel M, Just-Nubling G, Helm EB, et al. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses 1996; 39 Suppl. 1: 102–6

    Article  PubMed  Google Scholar 

  156. Cartledge JD, Midgley J, Gazzard BG. Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS 1997; 11(2): 163–8

    Article  PubMed  CAS  Google Scholar 

  157. Phillips P, Zemcov J, Mahmood W, et al. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996; 10(12): 1369–76

    Article  PubMed  CAS  Google Scholar 

  158. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33(9): 1529–35

    Article  PubMed  CAS  Google Scholar 

  159. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996; 334: 1674–5

    Article  PubMed  CAS  Google Scholar 

  160. Vecchiarelli A, Monari C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis 1995; 171(6): 1448–54

    Article  PubMed  CAS  Google Scholar 

  161. Swindells S, Kleinschmidt DR, Hayes FA. Pilot study of adjunctive GM-CSF (yeast derived) for fluconazole-resistant oral candidiasis in HIV-infection. Infect Dis Clin Pract 1997; 6: 278–9

    Article  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have provided no information on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, USA

    Jose A. Vazquez

Authors
  1. Jose A. Vazquez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose A. Vazquez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vazquez, J.A. Invasive Oesophageal Candidiasis. Drugs 63, 971–989 (2003). https://doi.org/10.2165/00003495-200363100-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363100-00004

Keywords

Search

Navigation